A Special Program for Phase I Clinical Trials
at Hackensack Meridian John Theurer Cancer Center

Join us today and support Phase 1 Clinical Trials. Your donation will have double the impact with a $100,000 matching gift* from the Edwin and Linda Siegel Family Foundation.

Click DONATE NOW to make a gift in support of our work today
or Click JOIN TEAM to start your own personal fundraising page in support of these efforts.

Every dollar raised through this page will have double the impact through the incredible generosity of Edwin and Linda Siegel Family Foundation with a matching gift. This matching gift will allow us to transform the Phase 1 Clinical Trials program at John Theurer Cancer Center. 

Phase 1 studies are the first step of evaluation of a new drug in patients. Our program, lead by Dr. Martin Gutierrez, offers patients the earliest access to promising new anticancer therapies.

We hope you will join them today to support this critical work and life-saving program.

More about Phase 1 and Dr. Gutierrez's program: John Theurer Cancer Center has the highest number of early-phase clinical trials in New Jersey. Our dedicated Phase 1 Clinical Trials Program enables patients to receive innovative therapies, including novel combinations, at the earliest stage of development.

In 2020, even with the COVID-19 setbacks, the Phase 1 program enrolled more patients than 2019 and opened an additional 13 studies. In 2020, Dr. Gutierrez became the first investigator in New Jersey to dose solid tumor patients with novel cellular therapies. Over the next several years the goal of the program is to expand, both here at Hackensack University Medical Center, Hackensack Meridian Health and additional sites throughout the tristate area. These centers will be dedicated to complex dose escalation and cellular therapy treatments for patients with solid tumors. 

*UNTIL MAXIMUM REACHED